Consensus Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
42.21 USD +0.17% Intraday chart for Cerevel Therapeutics Holdings, Inc. +0.86% -0.45%

Evolution of the average Target Price on Cerevel Therapeutics Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

56a7536b54f744522.sK4PJo5Q6BcUBhzpneTdZYKBVfjJzcwliTrbaqQwY0c.wsZqf-s5pSR3YXeO3qaHHeX0YauAu513u3zrHcoFBgXq-Tli-2XQcycwSQ~5a92dbc5313a978d4afbf76fc4e80986
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40 MT
TD Cowen Downgrades Cerevel Therapeutics to Market Perform From Outperform, Price Target is $45 MT
HC Wainwright Downgrades Cerevel Therapeutics to Neutral From Buy, Raises Price Target to $45 From $41 MT
Are rate cuts are coming early next year? Our Logo
Cantor Fitzgerald Downgrades Cerevel Therapeutics to Neutral From Overweight, Raises Price Target to $45 From $38 MT
Piper Sandler Downgrades Cerevel Therapeutics to Neutral From Overweight, Price Target is $45 MT
Piper Sandler Starts Cerevel Therapeutics Holdings at Overweight, $33 Price Target MT
Mizuho Cuts Price Target on Cerevel Therapeutics to $25 From $29, Keeps Neutral Rating MT
Morgan Stanley Adjusts Price Target on Cerevel Therapeutics to $42 From $46, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Cerevel Therapeutics to $41 From $45, Maintains Buy Rating MT
BofA Securities Downgrades Cerevel Therapeutics Holdings to Neutral From Buy, Adjusts Price Target to $31 From $36 MT
Berenberg Bank Adjusts Cerevel Therapeutics Price Target to $24 From $22, Maintains Hold Rating MT
Goldman Sachs Adjusts Price Target on Cerevel Therapeutics to $30 From $31, Keeps Neutral Rating MT
Mizuho Securities Adjusts Cerevel Therapeutics Price Target to $29 From $26, Maintains Neutral Rating MT
Wells Fargo Upgrades Cerevel Therapeutics Holdings to Overweight From Equalweight, Price Target is $30 MT
TD Cowen Initiates Cerevel Therapeutics Holdings at Outperform MT
JPMorgan Downgrades Cerevel Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $29 From $40 MT
Berenberg Bank Resumes Coverage on Cerevel Therapeutics With Hold Rating, $22 Price Target MT
Mizuho Cuts Price Target on Cerevel Therapeutics to $26 From $28, Keeps Neutral Rating MT
Morgan Stanley Adjusts Price Target on Cerevel Therapeutics Holdings to $40 From $50, Maintains Overweight Rating MT
Wells Fargo Downgrades Cerevel Therapeutics Holdings to Equalweight From Overweight, Adjusts Price Target to $30 From $38 MT
HC Wainwright Adjusts Price Target on Cerevel Therapeutics to $45 From $48, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
42.14 USD
Average target price
44.78 USD
Spread / Average Target
+6.26%
High Price Target
45 USD
Spread / Highest target
+6.79%
Low Price Target
43 USD
Spread / Lowest Target
+2.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cerevel Therapeutics Holdings, Inc.

Mizuho Securities
JPMorgan Chase
Jefferies & Co.
TD Cowen
HC Wainwright
Piper Sandler
Cantor Fitzgerald
Morgan Stanley
BofA Securities
Berenberg Bank
Goldman Sachs
Wells Fargo Securities
Loop Capital
Evercore ISI
Stifel Nicolaus
  1. Stock Market
  2. Equities
  3. CERE Stock
  4. Consensus Cerevel Therapeutics Holdings, Inc.